How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Spread the love“`html Artificial Intelligence (AI) has transcended its traditional role as a tool for human usage, evolving into a powerful force capable of creating and improving itself. This ...

OpenAI and Broadcom unveiled Jalapeño, a custom AI inference chip designed in nine months. Early tests show 50% cost savings over standard GPUs, with deployment planned for late 2026.

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Anthropic’s latest bombshell about AI designing itself and the dangers of the same, must be taken with a pinch of salt, ...

Most security teams think of NTFS junctions and symbolic links as niche file system features. They let one directory point to another, like a shortcut that the OS treats as real. They exist for ...

One of the world’s leading artificial intelligence companies has implored the industry to pause development on AI, because the latest models could be reaching a tipping point where they become capable ...

Yuandong Tian, who spent more than a decade as a research scientist director inside Meta's Fundamental AI Research lab, has surfaced as a co-founder of Recursive Superintelligence, a startup that ...

SoftBank CEO Masayoshi Son said OpenAI's next model is being designed by AI in a sign of "superintelligence." Son said his previous forecast of artificial superintelligence arriving in 10 years was ...

Anthropic reveals that Claude now writes over 80% of its production code, with engineers shipping 8x more code per quarter than in 2024. The company’s new Anthropic Institute paper maps the path to ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...